Thr37

Site Information
sRRAsPGtPLsPGsL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3208740
Available spectra: 3 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 )
Disease tissue studied:	breast cancer ( 3 ) , leukemia ( 9 ) , acute myelogenous leukemia ( 9 ) , lung cancer ( 1 , 4 , 5 , 8 ) , non-small cell lung cancer ( 4 , 5 , 8 ) , non-small cell lung adenocarcinoma ( 1 , 4 , 5 ) , non-small cell large cell lung carcinoma ( 4 )
Relevant cell line - cell type - tissue:	Cal-12T (pulmonary) ( 5 ) , Calu 6 (pulmonary) ( 8 ) , H2009 (pulmonary) ( 8 ) , H2077 (pulmonary) ( 8 ) , H2887 (pulmonary) ( 8 ) , H322M (pulmonary) ( 8 ) , HCC1359 (pulmonary) ( 8 ) , HCC2279 (pulmonary) ( 8 ) , HCC366 (pulmonary) ( 8 ) , HCC4006 (pulmonary) ( 8 ) , HCC44 (pulmonary) ( 5 ) , HCC78 (pulmonary) ( 8 ) , HCC827 (pulmonary) ( 8 ) , HeLa (cervical) ( 2 , 7 , 11 , 14 ) , HeLa S3 (cervical) ( 13 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 3 ) , HMLER ('stem, breast cancer') ( 3 ) , HOP62 (pulmonary) ( 8 ) , Jurkat (T lymphocyte) ( 10 , 12 ) , KG-1 (myeloid) ( 9 ) , LCLC-103H (pulmonary) ( 8 ) , LOU-NH91 (squamous) ( 8 ) , lung ( 4 , 5 ) , NCI-H1299 (pulmonary) ( 4 ) , NCI-H1395 (pulmonary) ( 8 ) , NCI-H1437 (pulmonary) ( 5 ) , NCI-H1568 (pulmonary) ( 8 ) , NCI-H157 (pulmonary) ( 8 ) , NCI-H1648 (pulmonary) ( 8 ) , NCI-H1666 (pulmonary) ( 5 , 8 ) , NCI-H1734 (pulmonary) ( 4 ) , NCI-H1944 (pulmonary) ( 4 ) , NCI-H2030 (pulmonary) ( 8 ) , NCI-H2172 (pulmonary) ( 8 ) , NCI-H2405 (pulmonary) ( 5 ) , NCI-H322 (pulmonary) ( 8 ) , NCI-H358 (pulmonary) ( 4 ) , NCI-H460 (pulmonary) ( 4 , 8 ) , NCI-H520 (squamous) ( 8 ) , NCI-H647 (pulmonary) ( 8 ) , PC9 (pulmonary) ( 1 , 8 ) , PC9-IR (pulmonary) ( 1 )

References
1	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
2	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
3	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
7	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
8	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
9	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
10	Guo A (2011) CST Curation Set: 11424; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
11	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
12	Possemato A (2010) CST Curation Set: 9396; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
13	Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48 18691976 Curated Info
14	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info